Understanding Immune Weakness in Sepsis
Sepsis-Associated Immune Suppression and F-box Proteins
This work explores how the immune system becomes weak during sepsis to find new ways to help patients recover from this severe infection.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11137636 on NIH RePORTER |
What this research studies
Sepsis is a very serious condition where the body's response to infection can become overwhelming, leading to organ damage and even death. While past efforts focused on reducing inflammation, this work explores a different problem: how the immune system becomes suppressed, making it harder for the body to fight off infection. We are exploring a specific protein, Fbxo24, which appears to weaken the immune system by getting rid of another important protein called DARS2. By understanding how Fbxo24 works, we hope to uncover new ways to support the immune system during sepsis and improve patient outcomes.
Who could benefit from this research
Good fit: This foundational work is not directly recruiting patients but aims to understand the underlying biology of sepsis, which could eventually benefit anyone who develops this severe infection.
Not a fit: Patients who do not have sepsis or conditions related to immune suppression during severe infection would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that strengthen the immune system in patients with sepsis, potentially improving recovery and survival.
How similar studies have performed: Previous approaches focusing solely on reducing inflammation in sepsis have not been very successful, making this focus on immune suppression a novel and important direction.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Mallampalli, Rama K — Ohio State University
- Study coordinator: Mallampalli, Rama K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.